Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
